All In Biotech

Drug Trial Radar · NCT07404553

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Jul 2028

Study completion Aug 2028

Sponsor

Sponsor type
Industry
First posted
Feb 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.

Conditions

  • Hypercholesterolemia

Interventions

  • SHR-1918 InjectionDrug

    SHR-1918 injection.

  • SHR-1918 Injection PlaceboDrug

    SHR-1918 injection placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in low density lipoprotein cholesterol (LDL-C) levels at Week 12 relative to baseline.Time frame: At 12 weeks of treatment.
  2. Percentage change in low density lipoprotein cholesterol (LDL-C) levels at Week 24 relative to baseline.Time frame: At 24 weeks of treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing First Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.